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Effect of hormone depletion on cell survival in the EMR-86 rat mammary
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Summary Growth of the transplantable EMR-86 rat mammary carcinoma depends on elevated prolactin
levels which are induced by oestrogenic stimulation of the pituitary. We investigated histological and cell
kinetic changes during tumour regression after removal of implanted oestrogen pellets (EP), and we especially
focused on the role of apoptosis. After EP removal, serum prolactin decreased to basal levels in 5 days,
reaching its largest depletion during the first day. Similarly, S-phase cell fractions, assessed by
bromodeoxyuridine (BrdUrd) incorporation, decreased to half the initial value during the first day and
developed into a gradual decrease to basal levels thereafter. Within 10 days, tumour volumes were reduced to
20% without striking changes in tissue architecture. To quantify apoptosis, we applied a method that stains
DNA breaks in tissue sections and subsequently measured the stained area by automated image cytometry.
This procedure was necessary, as the subtle changes could not be detected by histological examination alone.
One day after the rapid decline of the S-phase fraction, a 3-fold increase in apoptotic area was observed that
remained for about 3 days and then gradually decreased. This correlated with the histologically observed
reduction of tumour cells. In spite of the major cell loss, regression came to a halt after about 10 days. The
surviving cell fraction is discussed within the context of a stem cell hypothesis, in which tumour cells with stem
cell characteristics are less susceptible to hormone-induced apoptosis than their (non-stem) daughter cells. This
notion has implications for the eradication of residual tumour cells, because a diminished susceptibility might
also apply to apoptosis induced by radio- or chemotherapy.
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The importance of cell death, next to a decrease in
proliferation, is widely acknowledged in endocrine-induced
regression of mammary tumours. However, in vivo still little
is known about the relationship of the different cell kinetic
parameters in time and their effect on regression (Cutts and
Froude, 1968; Lancaster et al., 1988; Kyprianou et al., 1991).
In the early 1970s, rat model studies conducted by Gullino
and colleagues showed that endocrine-induced tumour
regression is not accompanied by striking changes in
histology, gross chemical composition, changes in blood
flow or by invasion of macrophages and leucocytes (Gullino
et al., 1972). They found no evidence for cell lysis by
extracellular factors and concluded that it involved an
autophagic process (Gullino and Lanzerotti, 1972).
Recent research has demonstrated that cells can initiate
their own death in response to endocrine as well as various
other types of anti-cancer treatment. This programmed cell
death, or apoptosis, involves activation of specific gene-
directed programmes that induce DNA fragmentation and
subsequent elimination of the cell (Arends et al., 1990). The
morphological aspect is reduction in cell volume, condensa-
tion of chromatin, fragmentation of the cell into small bodies
and rapid engulfment and digestion by neighbouring cells or
macrophages, without inducing inflammation (Kerr et al.,
1972; Wyllie et al., 1980). Apoptosis enables an orderly
regression with preservation of tissue architecture. It occurs
during the regression of normal mammary epithelium in the
menstrual cycle and also after weaning (Ferguson and
Anderson, 1981; Walker et al., 1989; Strange et al., 1992;
Guenette et al., 1994). Furthermore, it is found in mammary
tumours after hormonal ablation (Kyprianou et al., 1991;
Rennie et al., 1988).
Previously, we described the transplantable EMR-86 rat
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mammary carcinoma, which requires elevated prolactin levels
for growth. After hormonal ablation, tumours regress
rapidly, accompanied by a rapid decrease in proliferative
activity (Wijsman et al., 1991). We have now used this EMR-
86 model for a quantitative analysis of decreasing hormone
levels and subsequent changes in proliferation and cell death.
These changes were related to tumour volume reduction and
histology. Furthermore, changes in the fraction of tumour
cells compared with stromal cells were evaluated. Prolifera-
tion was assessed by bromodeoxyuridine (BrdUrd) incorpora-
tion. Apoptosis was quantified by automated image
cytometry, measuring the area of DNA fragmentation in
tissue sections after in situ end labelling (ISEL) (Wijsman et
al., 1993). Finally, we will discuss the fact that regression is
finite, with only a fraction of cells surviving that are
apparently less susceptible to apoptosis than the majority of
cells.
Materials and methods
Tumour model and experimental protocol
Thirty-five female WAG/Olac rats (a Wistar-derived strain,
Harlan/Olac, Zeist, The Netherlands) of 180-200 g were
given subcutaneously (s.c.) two EMR-86 tumour transplants
from frozen stock in each flank and an oestrogen pellet (EP,
containing 1.5 mg 17f-oestradiol) in the neck. EMR-86
tumours only grow in the presence of supraphysiological
levels of prolactin (Wijsman et al., 1991). These are induced
by oestrogenic stimulation of the pituitary via the EPs. By
inserting or removing the EP, tumour growth and regression
can be manipulated. Tumours are histologically classified as
invasive ductal carcinoma with a cribriform growth pattern
and areas with comedo-type necrosis. About 30 days after
transplantation, tumours had reached a volume of + 1 cm3
and pellets were removed to induce regression. At 0, 0.25, 1,
2, 3, 4, 5, 7 and 10 days after EP removal, rats were sacrificed
by cardiac puncture under ether anaesthesia. This method
was chosen to collect serum for prolactin measurements.Apoptosis in hormone-dependent tumour regression
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Tumours were immediately excised and processed for
histology and flow cytometry.
Tumour volume measurements
Tumours were measured using calipers and volumes were
calculated by the product of three orthogonal diameters
multiplied by n/6. (Dethlefsen et al., 1968). A volume
regression curve was constructed using data from a different
experiment in which 26 rats bearing a total of 50 EMR-86
tumours were measured daily for 2 weeks after EP removal.
Radioimmunoassay ofserum prolactin
Prolactin was determined by means of a standard radio-
immunoassay based on the following reagents: anti-rPRL-S8,
iodination preparation rPRL-15 and standard preparation
rPRL-RP3. These reagents were kindly provided by the
NIDDK, National Hormone and Pituitary Program of the
National Institute of Health (University of Maryland School
of Medicine, USA).
Detection ofbromodeoxyuridine incorporation
To determine the BrdUrd labelling index (LI), an estimate of
the S-phase fraction, rats were administered a single
intraperitoneal injection of 50 mg of 5-bromodeoxyuridine
kg-' (Sigma) 1 h before sacrifice.
DNA-incorporated BrdUrd was detected in tissue sections
using the IU-4 anti-BrdUrd monoclonal antibody (a gift from
Caltag, San Fransisco, CA, USA) in an indirect immunoper-
oxidase technique, described previously (Wijsman et al.,
1991). Nuclei (500-1000) of tumour cells were scored to
determine the BrdUrd labelling index (LI).
Quantitation of apoptosis
Apoptosis was quantified by automated image cytometry
after histochemical staining by in situ end-labelling (ISEL).
This involves the enzymatic incorporation of labelled
nucleotides into the fragmented DNA of apoptotic cells
(Wijsman et al., 1993). Paraffin sections of 2 ,um thick were
dewaxed, rehydrated and incubated in preheated 2 x SSC
(0.3 M sodium chloride and 30 mM sodium citrate, pH 7.0) at
80°C for 20 min, followed by thorough washing in distilled
water. This heating step enhances uniform permeation by
subsequent protease digestion, which consisted of immersing
the sections in 0.5% pepsin (0.9 mAnson U mg-'; Serva,
Heidelberg, Germany) in hydrochloric acid (pH 2.0) under
gentle agitation at 37°C for 15 min. Digestion was stopped by
washings in phosphate-buffered saline (PBS). Subsequently,
sections were rinsed in buffer A [containing 50 mM Tris-HCl,
5 mM magnesium chloride, 10 mM f,-mercaptoethanol and
0.005% bovine serum albumin (BSA) (Fraction V; Sigma, St.
Louis, MO, USA), pH 7.5], and after removal of excess
buffer incubated for 1 h at 15°C with buffer A containing
0.01 mM dATP, dCTP and dGTP (Boehringer, Mannheim,
Germany), 0.01 mM biotin-11-dUTP (Sigma) and 10 U ml-'
E. coli DNA polymerase I (Gibco BRL, Gaithersburg, MD,
USA). The reaction was stopped by washing briefly in
running tap water, followed by blocking of endogenous
peroxidase in PBS containing 0.1% hydrogen peroxide
(H202) for 15 min, and after two washings in PBS, sections
were incubated with horseradish peroxidase-conjugated
avidin (Vector, Burlingame, CA, USA), diluted 1:100 in
PBS containing 1% BSA and 0.5% Tween 20 for 30 min at
room temperature. Staining was developed in diaminobenzi-
dine-hydrogen peroxide (DAB) and nuclei were counter-
stained with methyl green for 30 min after a 10 min
incubation in 0.1 M sodium acetate buffer (pH 4). Under
these conditions, background staining of non-apoptotic cells
was not detectable (Wijsman et al., 1993), which is essential
for image cytometry.
ISEL-stained sections were analysed with a CAS 200 D
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image analysis system (Becton Dickinson Cellular Imaging
Systems, Leiden, The Netherlands). This is a microscope-
based two colour system that uses two solid-state image
sensing channels, a 520 nm channel to detect the DAB signal
and a 620 nm channel to detect the nuclear stain, including
the labelled cells. Both analogue video signals are digitised,
and light intensity values converted by an input lookup table
to optical density values, based on previous standardisation
and calibration of the instrument. During standardisation,
visual examination of the microscopic image verified that all
DAB stain was recognised. Sections of at least two tumours
per rat were thus analysed, measuring the total area of DAB-
positive apoptotic bodies and the total nuclear area in 15 to
25 randomly selected fields per section. In this fashion,
apoptosis could be expressed as the percentage DAB-stained
area of the total nuclear area. Microscopical validation of
every measured field assured that all labelled cells had the
morphological characteristics of apoptosis. Only tumour cells
were measured, whereas areas of necrosis and stroma were
excluded, using a mouse to manually define the region of
interest in the digitised image.
DNA ploidy measurements to estimate thefraction of tumour
cells
Since we have found previously that EMR-86 tumour cells
have an aneuploid DNA index of 1.4 (Wijsman et al., 1991),
DNA flow cytometry was used to estimate the fraction of
tumour cells relative to the diploid stromal cells. Suspensions
of single nuclei were prepared from 40-,m-thick cryostat
sections according to the method described by Vindelv et al.
(1983), and stained with propidium iodide (Sigma). Samples
were measured on a FACScan flow cytometer (Becton
Dickinson, Mountain View, CA, USA). By gating the Goj
peaks of tumour and diploid cells and measuring the number
of events within each gate, the ratio of the tumour cells and
the total number of cells could be calculated.
Results
Tumour volume, prolactin, S-phasefraction andfraction of
malignant cells
In EP-stimulated rats, EMR-86 tumours grew rapidly, with a
volume doubling time of 3 days. Following EP removal,
tumour volumes started to decrease after about 1 day. After 5
days, tumours had regressed to 50% of their initial volume,
and after 10 days to 20% (Figure la). After 14 days, further
regression was only marginal. Earlier studies showed that the
tumours remained palpable as small nodules for more than 3
months after EP removal (Wijsman et al., 1991).
Prolactin levels responded rapidly upon EP removal, since
a decrease was already detectable after 6 h; after 1 day levels
had almost halved (Figure lb). After 10 days, prolactin levels
were dramatically decreased. The decrease in cell prolifera-
tion, assessed by BrdUrd labelling, was even more rapid than
the decline of prolactin levels. After 1 day, the BrdUrd-LI
was less than half the initial value. After 10 days BrdUrd-LIs
were about 1% (Figure 1c).
The fraction of malignant cells in the tumour remained
relatively stable for the first 3 days after EP removal, but
progressively decreased afterwards. This indicated that the
tumour cells died more rapidly than the stromal cell
population. After 10 days, about half of the total cell
population consisted of stromal cells, whereas this was only
20% in EP-stimulated tumours (Figure le).
Quantitation of apoptosis
Identification of apoptosis was greatly facilitated by in situ
end-labelling (Figure 2). However, reproducible quantitation
of apoptosis by visual examination remained difficult in
EMR-86 tumours because (1) apoptosis was an infrequent
event, necessitating the counting of thousands of cells perApoptosis in hormone-dependent tumour regression
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Figure 2 Example of ISEL stained apoptotic cells and bodies in
a regressing EMR-86 tumour, three days after EP removal. x 400.
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Figure 1 Changes in (a) tumour volume (mean+s.d.), (b) serum
prolactin, (c) BrdUrd-LI, (d) apoptotic area and (e) fraction of
malignant cells in EMR-86 tumour-bearing rats after EP-removal
(O, the average of at least two tumours per rat).
section, and (2) apoptotic cells range morphologically from
relatively large condensed nuclei to small, scattered bodies,
which frustrated the establishing of objective scoring criteria.
Therefore, we used automated image cytometry and
measured the ISEL-stained area.
The measurements were validated in several ways. First,
the reproducibility of interactive image segmentation was
evaluated by measuring the same field ten times; each time
the thresholds were reset, which yielded a coefficient of
variation (CV) of 9%. Second, the apoptotic index of the
section was assessed ten times, each time resetting the
thresholds and measuring 20 randomly selected fields, which
yielded a CV of 12%. Measurements executed by other
investigators showed identical results. Third, image cytometry
was correlated with conventional counting using the
involuting rat prostate model (Wijsman et al., 1993) that, in
contrast to EMR-86 tumours, permits visual quantitation. In
the simple epithelial lining of the prostate gland the non-
labelled cells can be counted easily, and mainly distinct
apoptotic cells are present, whereas fragmented bodies have
disappeared into the lumen. In 14 rat prostates from 0 to 7
days after castration, a high correlation coefficient of 0.97
was found between the percentage ISEL-stained area and the
number of visually counted ISEL-stained apoptotic cells.
In the EMR-86 model, apoptotic cells were already present
in growing tumours. Image cytometry showed that they
represent a total area of 0.38+0.13% (mean+s.d.). After EP
removal, a more than 3-fold increase in ISEL-stained area
was observed from days 2 to 4. At day 4 a large variation
was found; the rat with the lowest value was also the one
with the highest prolactin level at day 4. The average values
after 7 and 10 days remained higher than at day 0 (Figure
ld).
In the tumour stroma apoptotic cells were detectable
during regression as well, but these cells were not included in
the measurements.
Morphological changes
Growing EMR-86 tumours showed large lobules of
carcinoma cells with a cribriform growth pattern and areas
with comedo necrosis (Figure 3a). Many mitotic figures and
also apoptotic bodies were observed. At 1 and 2 days after
EP removal no differences compared with EP-stimulated
tumours were detectable, except for reduced mitosis (Figure
3b). Apoptotic cells were more or less randomly distributed
within the tumour lobules, although fewer seemed present in
the basal layer. Their number appeared to increase from days
2 to 5, but the difference from day 0 was not very
conspicuous.
Three days after EP removal the lobules became smaller in
size (Figure 3c). This continued on days 4 and 5, whereas the
stromal area appeared relatively increased (Figure 3d).
During this period the areas of comedo necrosis became
smaller in size and number. No other patterns of necrosis
were noticed. After 7 days, the number of tumour cells
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Figure 3 Histology of EMR-86 tumours at (a) 0, (b) 2, (c) 3, (d) 5 and (e) 10 days after EP removal. See text for description.
Haematoxylin and eosin. x 200.
continued to decrease. At day 10, only small clusters of
tumour cells remained, in which some apoptotic cells were
still detectable (Figure 3e). Summarising, regression appeared
morphologically to be a very orderly process. The ductal
growth pattern remained preserved, only tumour cell
numbers were drastically reduced, as illustrated by the low-
power micrographs of Figure 3.
Macroscopically, growing EMR-86 tumours are highly
vascularised, but 10 days after EP removal the large vessels
supplying the tumour had disappeared. This was not
quantitated, but it shows that non-tumour stromal compo-
nents also respond (rapidly) to the regression.
Discussion
We previously described the rapidly growing EMR-86
mammary carcinoma that quickly regresses after removal of
the growth stimulus (Wijsman et al., 1991). In the current
study we investigated the histological and cell kinetic changes
of regression, and focused on the contribution of apoptotic
cell death to this process. As shown in Figure 1, the rapid
decline of the BrdUrd-LI at day 1 and its further decrease,
which reached basal levels at day 5, was almost parallel to the
decrease in serum prolactin. With falling hormone levels, a
gradual decline in cell cycling activity instead of an instantApoptosis in hormone-dependent tumour regression
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cessation, suggests cellular heterogeneity towards the
hormonal threshold levels that determine cell proliferation.
We are currently trying to determine if this variability is
reflected by differences in cellular hormone receptor contents.
Not only tumourcells but also stromal cells were lost during
regression because we noticed the disappearance of blood
vessels and observed apoptosis in the stroma of ISEL-stained
tumours. Stromal cell loss is further illustrated by the constant
ratio of malignant and stromal cells during the first 3 days of
regression, despite a volume reduction to 75% of the initial
value. After this period, the fraction ofmalignant cells started
to decrease. Longer survival of macrophages in comparison
with tumour cells and fibroblasts may account for this, since
these cells have a potential role in the removal of apoptotic
debris. Unpublished experiments showed a large proportion of
immunohistochemically detectable macrophages in EMR-86
stroma. In involuting rodent mammary glands, Walker et al.
(1989) observed endothelial apoptosis and an increase of
interstitial and intraepithelial macrophages.
To measure cell death in this model, in situ end-labelling
(ISEL) was used (Wijsman et al., 1993). This staining method
facilitates recognition of apoptotic cells in tissue sections that
are otherwise difficult to detect, particularly when these cells lie
scattered in solid fields of polymorphic tumour nuclei instead
ofnormal single layer epithelium, such as that ofthe prostate.
The usefulness of the method has recently been confirmed by
others (Landstrom et al., 1994). However, difficulties in
quantifying apoptosis by visual counting remained, as only
subtle changes were detected. The increase concerned, roughly
estimated, less than 1% ofthe total number ofcells, as growing
EMR-86 tumours already contained a certain amount of
apoptotic cells. For the same reason we were unable to show
an increase of the characteristic DNA laddering in agarose
gels, which was further hampered by debris from the necrotic
areas (data not shown). Only with image cytometry objective
measurements of ISEL-stained sections became possible that
allowed detection ofchanges in apoptosis that could otherwise
not be quantified. These changes were relative, since estimation
ofthe absolute number ofapoptotic cells was not possible with
the available software.
The period of increased apoptosis correlated well with the
histologically observed reduction of tumour cells (Figure 3).
The change in tumour volume was more gradual (Figure la),
because of the slower decrease of the stromal compartment.
Since the necessary parameters to define a growth equation
(e.g. rate of cell loss and cell doubling) could not be obtained
in this model, it was impossible to link cell kinetic data
directly to the measured volume regression.
The present study does not support the hypothesis that
entering the S-phase is required before entering the apoptotic
pathway, as reported by Colombel and colleagues. They
detected a large fraction of BrdUrd-positive apoptotic cells in
regressing prostates after 6 h of BrdUrd labelling (Colombel
et al., 1992). In regressing EMR-86 tumours, the increase in
apoptosis lagged 1 day behind the decline in S-phase.
Another indication that tumour cells may survive for a
considerable length of time after the last cell division came
from continuous BrdUrd labelling experiments in EP-
stimulated EMR-86 tumours (Wijsman et al., 1992). The
percentage of BrdUrd-positive apoptotic nuclei after 6, 24
and 96 h of labelling was 13, 43 and 72 respectively
(unpublished results). Thus, after 96 h of labelling, more
than a quarter (28%) of the apoptotic cells had not
incorporated the label, suggesting that they had not divided
in the 4 days before their death. These data indicate that in
growing EMR-86 tumours a substantial and variable time
span exists between the exit from S-phase and apoptosis. This
heterogeneity may explain why the period of increased
apoptosis lasts more than 3 days. In contrast, the peak
incidence of apoptosis in involuting rat prostates lasts only 1
day, i.e. the second day after castration (Sandford et al.,
1984; English et al., 1992).
We previously demonstrated that after 10 days tumour
volumes decreased only a little further and that after 30 days,
small nodules persisted that remained dormant formore than a
year unless they were restimulated. The morphological
appearance of these dormant tumours was not substantially
different from those after 10 days and they still contained
proliferating cells. This residual cell cycling activity could not
be reduced by additional hormonal treatment. Therefore, the
surviving cells were regarded as tumour stem cells (Wijsman et
al., 1991). Wyllie has hypothesised on the role ofapoptosis in a
stem cell model to explain the regulation of cell numbers in
renewing tissues (Wyllie, 1992). A small population of stem
cells, possibly infrequently dividing, gives rise to a highly
proliferative 'amplification' compartment in which the cell
population rapidly expands. These cells undergo a number of
divisions before they become terminally differentiated. In this
model, the population size is predominantly determined in the
amplification compartment because its cells, possessing a high
proliferative potential, also have a high susceptibility to
apoptosis. This follows from studies by Evan and colleagues,
demonstrating that when the c-myc proto-oncogene is up-
regulated (as in cells competent to enter the cell cycle), cells
eithercontinuously proliferate or become apoptotic, depending
on the availability ofcritical growth factors (Evan et al., 1992).
Applying this stemcell hypothesis to EMR-86 tumour kinetics,
the increase in apoptosis and subsequent regression can be
interpreted as a reduction of the amplification compartment,
while cells surviving after 10 days are intrinsically less
susceptible to hormone-induced apoptosis and can be
regarded as tumour stem cells. Accepting the existence of
such hierarchy in (hormone-dependent) carcinomas is impor-
tant, as the residual cells may also be more 'resistant' to other
apoptotic stimuli such as radio- and chemotherapy.
In conclusion, regression of the EMR-86 tumour after
hormonal withdrawal is a rapid process that leaves tissue
architecture intact. EP removal results in an almost
immediate drop of prolactin levels and a simultaneous
decrease in proliferation. After 1 day, this is followed by a
temporary increase in apoptosis. This period correlates with
the histologically observed tumour cell reduction. Although
apoptotic cells represent only a small fraction of the total cell
population, they can be effectively measured by image
cytometry after being stained with the ISEL procedure.
In spite of rapid cell loss, regression is finite. A stem cell
concept could explain this observation and it is important to
realise that tumour cells that survive hormonal regression and
remain in a dormant state afterwards, may also be less
sensitive to other apoptotic stimuli.
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